ReviewMethodist DeBakey cardiovascular journal2023
Vasoplegia: A Review.
Review in Methodist DeBakey cardiovascular journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Vasoplegia in Cardiac Surgery and Mechanical Circulatory Support: From Cardiopulmonary Bypass to Advanced Circulatory Support Devices.Journal of cardiovascular development and disease · 2026Review
- Recent perioperative challenges in anesthesia during expansion of heart transplantation.Journal of cardiothoracic surgery · 2026Review
- Extracorporeal Cytokine Hemadsorption with oXirisJournal of clinical medicine · 2026Article
- Preoperative Intestinal Preconditioning to Prevent Postoperative Vasoplegia After Tricuspid Valve Surgery.Annals of thoracic surgery short reports · 2026Article
- Effect of preoperative vitamin B12 levels on postoperative outcomes in CABG patients.Turk gogus kalp damar cerrahisi dergisi · 2026Article
- From Fluid Responsiveness to Prognosis: The Emerging Role of Point-of-Care Echocardiography in Sepsis.Diagnostics (Basel, Switzerland) · 2025Review
- ApoA1/HDL and sepsis-associated vascular endothelial injury: a narrative review.Critical care (London, England) · 2025Review
- ATPflugers Archiv : European journal of physiology · 2025Article
- Management of hypotension in dihydropyridine calcium channel blocker overdose: The role of high-dose insulin therapy.British journal of clinical pharmacology · 2025Article
- Prognostic value of the vasoactive-inotropic score in predicting outcomes following LVAD implantation.JHLT open · 2025Article
- Management of vasoplegic shock.BJA education · 2025Review
- Vasoplegic Syndrome Following Bypass: A Comprehensive Review of Pathophysiology and Proposed Treatments.Cureus · 2025Review
- Low systemic vascular resistance with normal blood pressure: Do we need vasopressors?PloS one · 2025Article
- Article
- Dopamine, norepinephrine, and vasopressin accelerate particle transport velocity in murine tracheal epithelium via substance-specific receptor pathways: dependency on intra- and extracellular CaFrontiers in pharmacology · 2024Article
- Vitamin B12 (hydroxocobalamin) administration in the management of persistent vasoplegic shock.Saudi journal of anaesthesiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasoplegia is a condition characterized by persistent low systemic vascular resistance despite a normal or high cardiac index, resulting in profound and uncontrolled vasodilation. Vasoplegia may occur due to various conditions, including cardiac failure, sepsis, and post-cardiac surgery. In the cardiac cohort, multiple risk factors for vasoplegia have been identified. Several factors contribute to the pathophysiology of this condition, and various mechanisms have been proposed, including nitric oxide, adenosine, prostanoids, endothelins, the renin-angiotensin-aldosterone system, and hydrogen sulfide. Early identification and prompt management of vasoplegia is crucial to prevent development of shock. This review expands upon the different vasopressors used in management of vasoplegia, including catecholamines such as norepinephrine, dopamine, epinephrine, phenylephrine, and other agents including vasopressin, methylene blue, angiotensin II, hydroxocobalamin, vitamin C, thiamine, and corticosteroids (ie, hydrocortisone). It also emphasizes the importance of conducting further research and making advancements in treatment regimens for vasoplegia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.